文献速递头颈与中枢神经肿瘤

头颈部鳞状细胞癌根治性放疗中降低选择性照射剂量的临床获益与安全性:UPGRADE-RT多中心随机对照试验

Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2025-04-15

这项荷兰五中心随机对照试验将300例cT2-4N0-2M0头颈部鳞癌患者按2:1随机分配至选择性颈部照射剂量降低组(43 Gy)或标准组(50 Gy),1年饮食正常度评分两组无显著差异,降低组2年选择性照射淋巴结复发率为4.9%(单侧95%CI上限7.5%),探索性分析显示降低组急性吞咽困难≥3级更少且口干相关生活质量更好。

要点

  • 降低选择性颈部照射剂量至43 Gy与标准50 Gy相比,1年饮食正常度评分无显著差异。
  • 降低组2年选择性照射淋巴结复发率4.9%,单侧95%CI上限7.5%,低于预设9%的无效假设上限。
  • 探索性分析显示降低组急性吞咽困难≥3级更少,口干相关生活质量更好。

核心结论

  • 这是第二项证明在头颈部癌根治性放疗中降低选择性照射剂量是安全的随机对照试验。

研究设计与样本

  • 多中心随机对照试验,在五个荷兰中心纳入新诊断的cT2-4N0-2M0头颈部癌患者,接受根治性加速放疗68 Gy分34次5.5周,接受同步化疗者不符合条件。
  • 选择性颈部照射剂量按2:1随机分配至剂量降低组43 Gy或对照组50 Gy。
  • 共300例患者随机分配,295例可评估并纳入分析(剂量降低组196例,对照组99例),随机分配时间为2016年至2022年。

主要发现

  • 1年饮食正常度评分均值:剂量降低组91.6(95%CI 88.5至94.7),对照组92.6(95%CI 88.2至97.1),均值差-1.1(95%CI -6.5至4.4)。
  • 剂量降低组2年选择性照射淋巴结复发率为4.9%(单侧95%CI上限7.5%),对照组为4.3%(单侧95%CI上限7.7%)。
  • 探索性分析显示剂量降低组急性吞咽困难≥3级更少,口干相关生活质量更好。

关键数值与推荐

  • 主要结局为1年饮食正常度评分。
  • 次要结局为剂量降低组2年选择性照射淋巴结复发率,若单侧95%CI上限超过9%则拒绝无效假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Definitive radiotherapy (RT) for head and neck cancer (HNC) has significant long-term toxicity with elective neck irradiation (ENI) as a major contributor. In this multicenter randomized trial, the clinical benefit and safety of definitive RT with reduced versus standard elective dose were compared. METHODS: Newly diagnosed patients with cT2-4N0-2M0 HNC were accrued and treated in five Dutch centers (definitive accelerated RT, 68 Gy in 34 fractions in 5.5 weeks). Patients receiving concurrent chemotherapy were not eligible. Dose for ENI was randomly assigned (2:1; dose reduction, 43 Gy, versus control, 50 Gy). The primary outcome was normalcy of diet score at 1 year. The secondary outcome was recurrence in electively irradiated nodes at 2 years in the dose reduction group with the null hypothesis rejected if the upper-bound one-sided 95% CI exceeded 9%. RESULTS: Between 2016 and 2022, 300 patients were randomnly assigned, of whom 295 were evaluable and included in analysis (dose reduction, 196 and control, 99). The mean normalcy of diet score at 1 year was 91.6 (95% CI, 88.5 to 94.7) in the dose reduction group and 92.6 (95% CI, 88.2 to 97.1) in the control group (mean difference, -1.1 [95% CI, -6.5 to 4.4]). The 2-year recurrence rate in electively irradiated nodes in the dose reduction group was 4.9% (upper-bound one-sided 95% CI, 7.5%). In the control group, this was 4.3% (upper bound one-sided 95% CI, 7.7%). Exploratory analyses demonstrated less acute dysphagia grade ≥3 and better xerostomia-related quality of life in the dose reduction group. CONCLUSION: This is the second randomized controlled trial demonstrating that reduced elective dose is safe in definitive RT for HNC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. van den Bosch S, Doornaert PAH, Hoebers FJP, et al. Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial. J Clin Oncol. 2025. PMID: 40233286. doi:10.1200/JCO-24-02194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。